Olympus Corporation (FRA:OLY1)

Revenue by Geography

Financials in millions JPY. Fiscal year is April - March.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016	FY 2015	FY 2014	FY 2013
Period Ending	Sep 30, 2025	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021	Mar 31, 2020	Mar 31, 2019	Mar 31, 2018	Mar 31, 2017	Mar 31, 2016	Mar 31, 2015	Mar 31, 2014	Mar 31, 2013
Japan Revenue	106.84B	110.11B
North America Revenue	397.59B	413.81B
Europe Revenue	258.15B	254.62B
China Revenue	85.49B	95.72B
Asia and Oceania Revenue (Post-FY2019 Reporting)	97.62B	93.69B
Asia and Oceania Revenue (Pre-FY2020 Reporting)	183.11B	189.41B
Other Countries Revenue	31.62B	28.84B

Revenue Breakdown

Financials in millions JPY. Fiscal year is April - March.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016	FY 2015	FY 2014	FY 2013
Period Ending	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021	Mar 31, 2020	Mar 31, 2019	Mar 31, 2018	Mar 31, 2017	Mar 31, 2016	Mar 31, 2015	Mar 31, 2014	Mar 31, 2013
Endoscopic Solutions Division Revenue	636.14B
Therapeutic Solutions Division Revenue	360.66B
Total Medical Solutions Division Revenue	996.80B
Other Division Revenue (Post-FY2024 Reporting)	530.00M

Revenue Breakdown 2

Financials in millions JPY. Fiscal year is April - March.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016	FY 2015	FY 2014	FY 2013
Period Ending	Sep 30, 2025	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021	Mar 31, 2020	Mar 31, 2019	Mar 31, 2018	Mar 31, 2017	Mar 31, 2016	Mar 31, 2015	Mar 31, 2014	Mar 31, 2013
Gastrointestinal Solutions Division Revenue	658.66B	674.04B
Surgical & Interventional Solutions Division Revenue	318.64B	322.76B

EBIT

Financials in millions JPY. Fiscal year is April - March.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016	FY 2015	FY 2014	FY 2013
Period Ending	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021	Mar 31, 2020	Mar 31, 2019	Mar 31, 2018	Mar 31, 2017	Mar 31, 2016	Mar 31, 2015	Mar 31, 2014	Mar 31, 2013
Endoscopic Solutions Division Operating Profit	141.40B
Therapeutic Solutions Division Operating Profit	61.45B
Total Medical Solutions Division Operating Profit	202.85B
Other Division Operating Profit (Post-FY2024 Reporting)	-473.00M
Eliminations from Division Operating Profit	-39.92B

EBIT 2

Financials in millions JPY. Fiscal year is April - March.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016	FY 2015	FY 2014	FY 2013
Period Ending	Sep 30, 2025	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021	Mar 31, 2020	Mar 31, 2019	Mar 31, 2018	Mar 31, 2017	Mar 31, 2016	Mar 31, 2015	Mar 31, 2014	Mar 31, 2013
Gastrointestinal Solutions Division Operating Profit	143.72B	167.89B
Surgical & Interventional Solutions Division Operating Profit	8.24B	14.69B

Key Performance Indicators

Financials in millions JPY. Fiscal year is April - March.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016	FY 2015	FY 2014	FY 2013
Period Ending	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021	Mar 31, 2020	Mar 31, 2019	Mar 31, 2018	Mar 31, 2017	Mar 31, 2016	Mar 31, 2015	Mar 31, 2014	Mar 31, 2013
ESD - GI Endoscopy Revenue Growth Rate After FX Adjustment	3.00%
ESD - Surgical Endoscopy Revenue Growth Rate After FX Adjustment	5.00%
ESD - Medical Service Revenue Growth Rate After FX Adjustment	5.00%
Total Endoscopic Solutions Division (ESD) Revenue Growth Rate After FX Adjustment	4.00%
TSD - GI EndoTherapy Revenue Growth Rate After FX Adjustment	2.00%
TSD - Urology Revenue Growth Rate After FX Adjustment	6.00%
TSD - Respiratory Revenue Growth Rate After FX Adjustment	10.00%
TSD - Other Therapeutic Areas Revenue Growth Rate After FX Adjustment	-7.00%
Total Therapeutic Solutions Division (TSD) Revenue Growth Rate After FX Adjustment	3.00%

Updated Sep 30, 2025. Data Source: Fiscal.ai.